P&G azimilide arrythmia trial recruiting 5,900 patients with low LVEF, low heart rate variability.
P&G AZIMILIDE ARRHYTHMIA TRIAL ENROLLING 5,900 PATIENTS at 600 sites worldwide, John Camm, MD, St. George's Hospital Medical School (London), said at a Procter & Gamble-sponsored symposium on antiarrhythmic drugs Aug. 26 at the European Society of Cardiology meeting in Stockholm. The "ALIVE" trial (Azimilide Post-Infarct Survival Evaluation) will study the effect of oral 75 mg and 100 mg azimilide dihydrochloride vs. placebo on recent post-myocardial infarction patients with a left ventricular ejection fractions ranging between 15%-35% and low heart rate variability, Camm stated.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth